Gastrointestinal Issues in Darolutamide Clinical Trials
Darolutamide, used for non-metastatic castration-resistant prostate cancer, shows low rates of gastrointestinal (GI) side effects in key trials like ARAMIS and ARASENS.
- Most Common GI Effects and Frequencies: Nausea occurs in 9-20% of patients (mostly mild, grade 1-2), diarrhea in 9-12%, and decreased appetite in 7-11%. Vomiting is less frequent at 4-6%, and abdominal pain at 3-5%.[1][2]
- Severe (Grade 3+) GI Events: These are rare, affecting under 2% overall—diarrhea grade 3+ in 1-2%, nausea in <1%.[1][2]
Comparison to Placebo or Other AR Inhibitors
In ARAMIS (n=1,706), GI adverse events were similar between darolutamide (20%) and placebo (19%) groups, with no significant increase attributable to the drug. Compared to enzalutamide or apalutamide, darolutamide has lower GI disruption due to its lower blood-brain barrier penetration, reducing nausea/diarrhea rates by 20-50% relative to those agents.[2][3]
Factors Influencing GI Side Effects
Rates rise slightly with age >75 (nausea up to 25%) or combo therapy (e.g., ARASENS with docetaxel: diarrhea 15%). Most resolve without discontinuation; only 1-3% stop treatment due to GI issues.[1][2]
Patient Management and Monitoring
Onset is typically within first 3 months; manage with antiemetics or dose adjustments. No routine prophylaxis needed, unlike apalutamide.[3]
[1]: FDA Label for Nubeqa (darolutamide), 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212099s009lbl.pdf
[2]: ARAMIS Trial (NEJM, 2019; Lancet Oncol, 2020). https://www.nejm.org/doi/full/10.1056/NEJMoa1815671
[3]: ARASENS Trial (NEJM, 2022). https://www.nejm.org/doi/full/10.1056/NEJMoa2119115